...
首页> 外文期刊>Foot and ankle international >Platelet-rich plasma efficacy versus corticosteroid injection treatment for chronic severe plantar fasciitis
【24h】

Platelet-rich plasma efficacy versus corticosteroid injection treatment for chronic severe plantar fasciitis

机译:富血小板血浆疗效与糖皮质激素注射治疗慢性重度足底筋膜炎的疗效

获取原文
获取原文并翻译 | 示例
           

摘要

Background: Chronic plantar fasciitis is a common orthopedic condition that can prove difficult to successfully treat. In this study, autologous platelet-rich plasma (PRP), a concentrated bioactive blood component rich in cytokines and growth factors, was compared to traditional cortisone injection in the treatment of chronic cases of plantar fasciitis resistant to traditional nonoperative management. Methods: Forty patients (23 females and 17 males) with unilateral chronic plantar fasciitis that did not respond to a minimum of 4 months of standardized traditional nonoperative treatment modalities were prospectively randomized and treated with either a single ultrasound guided injection of 3 cc PRP or 40 mg DepoMedrol cortisone. American Orthopedic Foot and Ankle Society (AOFAS) hindfoot scoring was completed for all patients immediately prior to PRP or cortisone injection (pretreatment = time 0) and at 3, 6, 12, and 24 months following injection treatment. Baseline pretreatment radiographs and MRI studies were obtained in all cases to confirm the diagnosis of plantar fasciitis. Results: The cortisone group had a pretreatment average AOFAS score of 52, which initially improved to 81 at 3 months posttreatment but decreased to 74 at 6 months, then dropped to near baseline levels of 58 at 12 months, and continued to decline to a final score of 56 at 24 months. In contrast, the PRP group started with an average pretreatment AOFAS score of 37, which increased to 95 at 3 months, remained elevated at 94 at 6 and 12 months, and had a final score of 92 at 24 months. Conclusions: PRP was more effective and durable than cortisone injection for the treatment of chronic recalcitrant cases of plantar fasciitis.
机译:背景:慢性足底筋膜炎是一种常见的骨科疾病,可能难以成功治疗。在这项研究中,自体富血小板血浆(PRP)是富含细胞因子和生长因子的浓缩的生物活性血液成分,与传统可的松注射液相比,可治疗对传统非手术治疗有抵抗力的慢性足底筋膜炎。方法:前瞻性将40例单侧慢性足底筋膜炎患者(对至少4个月的标准传统非手术治疗方式无效)无反应,并对其进行前瞻性随机分组,并采用3 cc PRP超声引导注射或40例单次超声引导治疗毫克DepoMedrol可的松。紧接在注射PRP或可的松之前(预处理=时间0)以及在注射治疗后3、6、12和24个月,所有患者均完成了美国骨科足踝学会(AOFAS)的后足评分。所有病例均进行了基线预处理X线照片和MRI检查,以证实对足底筋膜炎的诊断。结果:可的松组的治疗前平均AOFAS评分为52,最初在治疗后3个月提高至81,但在6个月时降低至74,然后在12个月时降至接近基线水平58,并持续下降至最终水平在24个月时得分为56。相比之下,PRP组开始时的平均AOFAS评分为37,在3个月时增加到95,在6和12个月时一直保持在94,最后在24个月时达到92。结论:PRP比可的松注射液治疗慢性顽固性足底筋膜炎更有效,更持久。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号